Keynote lectures

Are Transcranial Doppler (TCD) embolization, impaired cerebrovascular reserve, stenosis progression and silent infarctions suitable tools to select patients for CEA or CAS?

Peter Ringleb, Heidelberg, Germany

Thursday, December 07, 2017 | 09.00-10.00 | CAR 1 | LECTURE HALL B

Prof. Dr. med. Dipl. Inf. (FH) Peter Arthur Ringleb obtained his doctoral degree in 1994 after graduating his parallel studies in computer sciences and medicine in Giessen, Germany. Since 2014, he is Professor for Vascular Neurology and Head of the Neurovascular Service of the University Hospital Heidelberg. His research activities include acute stroke treatment, ultrasound in stroke as well as long-term effect of stentprotected carotid artery and intracranial stenting. Beyond several high-ranking publications, Prof. Ringleb is involved in numerous clinical trials as either Prinicipal Investigator, steering committee member or national coordinator. Within the last 9 years he held several offices: member of the German guideline “Treatment of carotid artery stenosis”, associate editor for Stroke, secretary and member of the managing board of the German Stroke Society, editor for “Gefaesschirurgie”, member of the steering committee of the German guideline “Acute Stroke Treatment”, and Associate Editor for the European Journal of Stroke.


Mechanical thrombectomy: which results can we expect in clinical routine? Exit light – enter night

Werner Hacke, Heidelberg, Germany

Thursday, December 07, 2017 | 11.30-12.40 | CAR 3 | LECTURE HALL B

Werner Hacke was Professor and Chairman of the Department of Neurology at the University of Heidelberg in Germany from 1987 until 2014 and is now a Senior Professor of Neurology at the Ruprecht Karls University in Heidelberg, Germany.

His main scientific and clinical interest is in acute stroke, critical care neurology and in stroke prevention. He has pioneered the field of thrombolysis for acute stroke and initiated several new management options for large infarctions including hypothermia and decompressive surgery.

He was the founding President (now honorary President) of the European Stroke Organization. He is a Past President of the German Neurological Society, the German Stroke Society and the German Interdisciplinary Society of Intensive Care Medicine. He is currently the President of the World Stroke Organization (WSO).

In 1998, he was the first European recipient of the Feinberg Award for Excellence in Stroke Research, and the first recipient of the Karolinska Stroke Award in 2004. He was awarded the Nonne-Medal in 2008, received the Presidents Award by the World Stroke Organisation (2008), the Mihara Award by the Mihara Foundation (Japan, 2009), the Jarecki Award (USA, 2009) and the Wepfer Award of the ESC in 2013. Prof Hacke is honorary member of numerous neurological and neuroradiological Societies. He also holds several honorary doctorates abroad and an honorary professorship by the Unisversidad dos Andes Santiago de Chile. He was chair of the steering committees of several acute treatment and secondary prevention trials.

Prof. Hacke has published >500 original articles listed in pubmed and SCI. He is the scientist with the highest citation rate worldwide (>50,000) in the field of Stroke and Vascular Neurology (h-index 103 (Web of Science) resp. 124 (Google Scholar)).


Targeting inflammatory processes in atherosclerosis

Claudia Monaco, Oxford, UK

Thursday, December 07, 2017 | 14.00-15.10 | CAR 4 | LECTURE HALL B

Claudia Monaco is Professor of Cardiovascular Inflammation at the Kennedy Institute of Rheumatology and an Honorary Consultant Cardiologist at the University of Oxford NHS Trust with a special interest in Echocardiography. She also heads the Mass Cytometry Facility at NDORMS. She trained as a Cardiologist (1998) and PhD (2001) at the Catholic University of Rome, Italy.

She was privileged to get involved in the field of inflammation in atherosclerosis when it was still in its infancy with the identification of a cytokine-dependent systemic inflammatory response in patients with acute coronary syndromes.

Her group was the first to establish innovative experimental methodology for the isolation, culture and pharmacological targeting of live cells from human atheroma lesions. Her Cardiovascular Inflammation Team is focused in dissecting the functions of pattern recognition receptors and their downstream signaling in the vasculature in health and disease.

She won several prizes and awards including a Marie Curie EU Fellowship, the Young Investigator Award of the International Society of Thrombosis (1997) and the First Prize of the Young Investigator Award of the European Society of Cardiology (ESC) in the category Thrombosis (2002), and the Oxford-Harrington Scholarship (2015). She is a Fellow of the European Society of Cardiology since 2007. Her lab has been funded over the years by several EU and BHF grants.


Rationale, design, and key findings from the International Registry of Acute Aortic Dissection (IRAD)

Santi Trimarchi, San Donato Milanese, Italy

Thursday, December 07, 2017 | 15.30-17.00 | AOR 3 | LECTURE HALL C

Santi Trimarchi is associated Professor of Vascular Surgery and Director of Vascular Surgery Residency Program at the University of Milan. He is Head of the section Vascular Surgery II, Director of the Thoracic Aorta Research Center at Policlinico San Donato Research Hospital, as well as Co-director of the Beta Lab – Biomechanics for Endovascular Treatment of the Aorta.

He serves as co-investigator and investigator in several international registries and trials. In addition, he is promoter and supervisor of a PhD program on aortic diseases, in collaboration with Utrecht University, the Netherlands, and the University of Michigan, Ann Arbor, USA.


Pathophysiological impact of diabetes on AAA disease

Ronald Dalman, Stanford, USA

Friday, December 08, 2017 | 09.30-10.45 | AOR 5 | LECTURE HALL C

Stanford Vascular Surgery has grown to become one of the largest academic vascular programs in the USA, with 18 full time vascular surgeons, vascular internists, and biomedical engineers working in 7 different hospitals and health care facilities in Northern California. The program trains 11 residents and fellows, finishing 3 graduates annually.

In addition to leading Vascular Surgery, Dr. Dalman Co-Directs the Cardiovascular Service Line and Cardiovascular Research Institute (CVI) at Stanford. Having served as Principal Investigator on multiple NIH grants. Dalman currently directs the CVI NIH T32 training grant entitled “Mechanisms and Innovation in Vascular Disease”.

Beyond Stanford, Dalman has served on the Residency Review Committee for Surgery of the Accreditation Council for Graduate Medical Education (USA), on the Vascular Surgery Board of the American Board of Surgery, on the Executive Committee of the Association of Program Directors in Vascular Surgery, as Program Chairman for the Society for Vascular Surgery Vascular Annual Meeting, and as President of the Western Vascular Society.


Genetics of AAA – what clinicians need to know in 2017

Philip Tsao, Palo Alto, USA

Friday, December 08, 2017 | 13.30-15.10 | AOR 7 | LECTURE HALL C

Philip Tsao is a Professor of Medicine (Cardiovascular Medicine) at Stanford University School of Medicine and is Associate Chief of Staff for Research and Development at the VA Palo Alto Health Care System. After receiving his PhD in Cardiovascular Physiology from Thomas Jefferson University, he completed post-doctoral training in cellular and molecular biology at Stanford University and subsequently joined the faculty. Dr. Tsao’s laboratory investigates the molecular underpinnings of vascular disease using a range of biochemical, molecular and physiological techniques. Specific research interests include (1) mechanisms regulating atherosclerotic and abdominal aortic aneurysm disease, (2) role of insulin resistance in cardiovascular disease, (3) genomic and transcriptomic discovery in human cardio-metabolic disease, and (4) biomarker identification (including genetic) for risk prediction.


Determinants of occupational radiation exposure and current practice of
radiation protection in the Hybrid OR

Bijan Modarai, London, UK

Friday, December 08, 2017 | 16.10-17.55 | CAR7 / PAD8 / AOR9 | LECTURE HALL B

Bijan Modarai qualified in medicine from Guy’s and St Thomas’ Hospital in 1998 and obtained a PhD in 2006. He completed his vascular surgical training in London and as a visiting Fellow at The Royal Prince Alfred Hospital in Sydney. He was appointed as a Senior Lecturer and Consultant Vascular Surgeon at Guy’s and St Thomas’ Hospitals in 2012. Since then he has led a translational programme of vascular research, producing over 50 high impact publications with several national/international prizes awarded to his research team. He was made Reader in Vascular Surgery in 2015 and appointed as a Hunterian Professor by The Royal College of Surgeons of England in 2016. He was awarded a Senior Fellowship by the British Heart Foundation in 2017. His clinical practice is focused on complex endovascular aortic repair which also informs research into radioprotection and the effects of radiation exposure during endovascular interventions. Mr Modarai is Programme Chair for the British Society for Endovascular Therapy and examines for the Fellowship of European Board of Vascular Surgery.


Technological perspectives for endovascular therapy of the lower limb

Thomas Zeller, Bad Krozingen, Germany

Friday, December 08, 2017 | 09.30-10.35 | PAD 4 | LECTURE HALL B

Dr. Thomas Zeller is an Associate Professor in the Angiology Division of the Universitaets-Herzzentrum Freiburg ∙ Bad Krozingen, Germany. He performs interventional angiology with more than 20 years of experience in this field. His main research interest is diagnostic and therapy of renal artery stenosis, optimization of endovascular therapy methods of peripheral arterial occlusive disease and optimization of non-invasive diagnostic methods in vascular medicine. He has performed a series of studies in these areas and has conducted numerous clinical trials. Furthermore, he is editorial board member of various scientific journals, e.g. VASA, EUROIntervention, Vascular Medicine, Catheterization Cardiovascular Interventions, Journal of Endovascular Therapy, He is the author of more than 200 peer reviewed original and review articles, editor of the textbook Vascular Medicine – Therapy and Practice as well as reviewer for European Heart Journal, Journal of American College of Cardiology and sub-journals, Circulation and sub-journals, The Lancet and others.


Population screening and intervention for vascular disease in Danish men (VIVA): a randomized controlled trial

Jes Sanddal Lindholt, Odense, Denmark

Friday, December 08, 2017 | 11.00-12.15 | PAD 5 | LECTURE HALL B

Prof. Lindholt graduated medical school in 1990 at Aarhus University, Denmark. He obtained a PhD in 1998 and his doctoral degree in medical sciences (DMSci) in 2010.

He completed his residency training in vascular surgery at Aarhus University Hospital (Skejby), Viborg Hospital, and Rigshospitalet, Copenhagen. Currently, Prof. Lindholt is Head of the Cardiovascular Centre of Excellence in Southern Denmark (CAVAC), Professor of Vascular Surgery at Odense University Hospital, and adjungated Professor in Vascular Epidemiology at Viborg Hospital, Aarhus University.

He was Principal Investigator of the Viborg study (1994-2009), one of the four RCTs providing the evidence for population based screening for abdominal aortic aneurysms. Later as part of the European Research Consortium “Fighting Aneurysmal Disease (FAD)”, he served as Principal Investigator of the VIVA trial 2008 – examining the benefits and harms regarding triple vascular screening for AAA, PAD and hypertension. Prof. Lindholt co-founded the Elitary Research Centre for Individualized Medicine in Arterial Disease (CIMA) at Odense University Hospital in 2012 and the DANCAVAS trial – a 7 step multifaceted cardiovascular screening trial for coronary arterial calcification, aortic and iliac aneurysms, and PAD, among others aiming for more individualized cardiovascular prevention. In all, these three population-based screening trials involved more than 100,000 participants.

He received the Odd Fellow Research prize in 2015 after recommendation from evaluation boards at all Danish Universities.

Prof. Lindholt published more than 225 peer reviewed articles (H-index of 37 (Web of Science)).


New insights into the genetics of primary varicosis

Andreas Fiebig, Kiel, Germany

Saturday, December 09, 2017 | 09.00-10.20 | VEN 1 | LECTURE HALL B

Andreas Fiebig obtained his PhD in Biochemistry and Biotechnology at the University of Münster/Germany (see publication in the Journal of Biochemistry in 2005). From 2005 onwards, he was privileged to get involved in the field of high throughput genetics at the Institute of Molecular Genetics in Kiel/Germany. He was the first to establish the genetic background of Chronic Venous Diseases (Heritability of chronic venous disease, Hum Genetic, 2009). In 2017, as part of a large German research group, he identified the first three risk loci for CVD in a GWAS attempt (Sci. Rep. 2017 Apr 4;7:45652).

As managing director of the competence network of chronic venous diseases (Kiel, Berlin), he is involved in various scientific and technical research projects since 2009. Andreas Fiebig also participates in international cooperation projects being project manager as well as speaker of the initiative of competence networks in Life Sciences.

From 2015 to 2017 he was director of the Initiative of competence networks in Life Sciences (Kiel, Berlin, Frankfurt) interacting with international research centers. Since 2017 he is senior director of the Initiative of competence networks in Life Sciences. As managing director of the corresponding operative platform (InterMedCon, since 2016) he will continue the international cooperation with Japan and the Netherlands including INTERREG-Programme MIND (“Medical Innovation Germany Netherland”, Münster, EU).

Specific research interests include (1) mechanisms regulating chronic venous diseases, (2) role of neoangiogenesis, (3) genomic and transcriptomic discovery in human chronic venous diseases disease, and (4) biomarker identification (including genetic) for risk prediction. Technical interests are full automated storage systems, new GWAS approaches, humanoid robotics, tracker technology for cardiovascular diseases and care management concepts.

Oral anticoagulation and DVT: what is the evidence and is there a need to anticoagulate every lower leg DVT?

Sebastian Schellong, Dresden, Germany

Saturday, December 09, 2017 | 11.45-12.55 | VEN 3 | LECTURE HALL B

Sebastian Schellong graduated from the University of Lübeck in Germany, in 1984. After completing his residency in internal medicine at Hannover Medical School, Professor Schellong served as the Head of the Division of Angiology in the Clinic for Cardiology Angiology and Pneumonology, at the Otto-von-Guericke-University in Magdeburg in Germany.

Since 1995, he has been Head of the Division of Angiology, faculty of medicine ‘Carl-Gustav-Carus’ at the Technical University in Dresden. In 1997 he was appointed as university lecturer for Internal Medicine at the Technical University, and was appointed as director of the University Center for Vascular Diseases there, in 2004.

Professor Schellong was appointed Professor of Internal Medicine/Angiology of the medical faculty of the Technical University of Dresden in 2004. Currently, he is the Head of internal medicine Department II at the Dresden-Friedrichstadt Municipal Hospital, Dresden in Germany. For more than 42 years he is the CEO of the Deutsche Gesellschaft für Angiologie, currently he is President elected for the term 2018-2019.

Professor Schellongs fields of investigation include: venous thromboembolism diagnosic modalities of deep-vein thrombosis (DVT) and pulmonary embolism (PE); prolonged DVT prophylaxis; ambulatory care of DVT patients, as well as arterial disease; measurement of muscle blood flow in peripheral arterial obstructive disease (PAOD); basics of doppler measurement of arterial resistance and stenosis; serodiagnosis and clinical course of systemic vasculitis. Sebastian Schellong has been involved in various committees for the pivotal clinical trials with new direct oral anticoagulants both for prophylaxis and treatment. He lectures internationally, and has published more than 250 papers in international peer-reviewed journals.